Synthetic biology — the engineering discipline of designing and building biological systems — is to the 21st century what semiconductor engineering was to the 20th: a platform technology that will reshape every industry it touches. DNA can now be read, written, and edited like software code. The companies building on this platform are creating new materials, foods, fuels, medicines, and manufacturing processes that weren’t possible using chemistry alone.

What Synthetic Biology Actually Is

Synthetic biology is the application of engineering principles to biological systems. Just as software engineers write code to create programs, synthetic biologists write DNA sequences to create biological functions. The process: design a DNA sequence that encodes a desired function (producing a protein, manufacturing a chemical, detecting a pathogen), synthesize the DNA (using companies like Twist Bioscience, which can produce custom DNA for ~$0.07 per base pair — down from $10 per base pair in 2000), insert it into a host organism (typically bacteria, yeast, or mammalian cells), and test whether the organism performs the desired function. The iterative cycle of design-build-test is accelerating as AI tools predict the effects of DNA sequences before they’re synthesized.

Commercial Applications Today

Materials: Bolt Threads creates spider-silk-inspired fabrics (used by Stella McCartney and Lululemon). Spiber produces structural proteins for textiles and automotive parts. Food: Impossible Foods uses genetically engineered yeast to produce heme (the molecule that makes meat taste like meat) for plant-based burgers. Perfect Day produces dairy proteins through fermentation — real whey and casein without cows. Medicine: Moderna’s mRNA technology (which powered COVID vaccines) is synthetic biology — custom-designed genetic sequences that instruct human cells to produce specific proteins. CAR-T cancer therapies engineer patients’ own immune cells to attack tumors. Industrial chemicals: Genomatica and LanzaTech produce commodity chemicals (nylon precursors, ethanol, jet fuel) from engineered microorganisms instead of petroleum.

The Indian Opportunity

India has a strong foundation for synthetic biology: deep talent in biology and biochemistry (multiple world-class institutions including IISc, NCBS, InSTEM), a large pharmaceutical manufacturing base, and growing government investment (the DBT’s Bioeconomy program). Indian synbio startups to watch: String Bio (methane-to-protein conversion for animal feed), Bugworks (antibiotic discovery using AI + synbio), and Sea6 Energy (seaweed-based biomaterials). The opportunity: India could become a global hub for bio-manufacturing, leveraging lower costs and existing pharma infrastructure.

CRISPR and Beyond: The Editing Revolution

CRISPR-Cas9 made gene editing programmable and accessible — but next-generation editors are expanding the toolkit. Base editors (developed by David Liu’s lab and commercialized by Beam Therapeutics) change single DNA letters without double-strand breaks, reducing off-target effects. Prime editors can insert, delete, or replace longer sequences with higher precision. Companies like Prime Medicine and Tessera Therapeutics are advancing these technologies toward clinical applications. The first CRISPR-based therapy, Casgevy for sickle cell disease, received FDA approval in 2023 — validating the regulatory pathway for gene editing in humans.

Beyond editing, synthetic biology encompasses engineered organisms for manufacturing. Ginkgo Bioworks (NYSE: DNA) designs microbes to produce flavors, fragrances, materials, and therapeutics — their cell programming platform has been used by companies including Bayer and Cronos. Zymergen (acquired by Ginkgo) focused on materials. The industrial biology market — using engineered cells as factories — could reach $30 billion by 2030. The platform shift: biology is becoming a programmable substrate. As design tools improve and DNA synthesis costs fall, the barrier to “building with biology” drops. The companies that master the design-build-test cycle at scale will define the next platform.

The platform shift is clear: biology is becoming a programmable substrate. As design tools improve and DNA synthesis costs fall, the barrier to “building with biology” drops. The companies that master the design-build-test cycle at scale will define the next platform. Investors are betting on synthetic biology as a foundational technology — comparable to software in the 1980s or the internet in the 1990s. The applications span therapeutics, materials, agriculture, and manufacturing. The 2026 inflection: whether engineered organisms move from pilot scale to industrial production.

For more deep tech analysis, explore our Deep Tech section.

Further Reading

Related: D2C Startup Playbook for India: Supply Chain, Marketing — Startup Nerve

Related: Down Rounds: Impact on Founders, Employees and Investors — The VC Wire

Dive deeper: This article is part of our comprehensive guide — Deep Tech: From Research Lab to Global Market.